Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter

被引：6
作者：
Businello, Gianluca [1 ]
Angerilli, Valentina [1 ]
Lonardi, Sara [2 ]
Bergamo, Francesca [2 ]
Valmasoni, Michele [3 ]
Farinati, Fabio [3 ]
Savarino, Edoardo [3 ]
Spolverato, Gaya [3 ]
Fassan, Matteo [1 ,2 ]
机构：
[1] Univ Padua, Dept Med DIMED, Padua, Italy
[2] Ist Ricovero & Cura Carattere Sci IRCCS, Veneto Inst Oncol, Padua, Italy
[3] Univ Padua, Dept Surg Oncol & Gastroenterol DISCOG, Padua, Italy
来源：
UPDATES IN SURGERY | 2023年 / 75卷 / 02期
关键词：
Gastric adenocarcinoma; Gastroesophageal junction adenocarcinoma; Biomarkers; Immunohistochemistry; ADVANCED GASTRIC-CANCER; TYROSINE KINASE INHIBITOR; FGFR2 GENE AMPLIFICATION; DOUBLE-BLIND; OPEN-LABEL; 1ST-LINE THERAPY; HER2; STATUS; PHASE-II; MICROSATELLITE INSTABILITY; GASTROESOPHAGEAL CANCER;
D O I：
10.1007/s13304-022-01330-5
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
The comprehensive molecular characterization of gastric and gastroesophageal junction adenocarcinomas has led to the improvement of targeted and more effective treatments. As a result, several biomarkers have been introduced into clinical practice and the implementation of innovative diagnostic tools is under study. Such assessments are mainly based on the evaluation of limited biopsy material in clinical practice. In this setting, the pathologist represents a key player in the selection of patients facilitating precision medicine approaches.
引用
收藏
页码：291 / 303
页数：13
相关论文
共 50 条
  • [1] Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
    Gianluca Businello
    Valentina Angerilli
    Sara Lonardi
    Francesca Bergamo
    Michele Valmasoni
    Fabio Farinati
    Edoardo Savarino
    Gaya Spolverato
    Matteo Fassan
    Updates in Surgery, 2023, 75 : 291 - 303
  • [2] Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma
    Joshi, Smita S.
    Maron, Steven B.
    Catenacci, Daniel V.
    FUTURE ONCOLOGY, 2018, 14 (05) : 417 - 430
  • [3] Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives
    Niclauss, Nadja
    Guetgemann, Ines
    Dohmen, Jonas
    Kalff, Joerg C.
    Lingohr, Philipp
    CANCERS, 2021, 13 (22)
  • [4] Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns
    Korpan, Martin
    Puhr, Hannah Christina
    Berger, Julia M.
    Friedrich, Alexander
    Prager, Gerald W.
    Preusser, Matthias
    Ilhan-Mutlu, Ayseguel
    CANCERS, 2025, 17 (03)
  • [5] Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma
    Brezden-Masley, Christine
    Fiset, Pierre O.
    Cheung, Carol C.
    Arnason, Thomas
    Bateman, Justin
    Borduas, Martin
    Evaristo, Gertruda
    Ionescu, Diana N.
    Lim, Howard J.
    Sheffield, Brandon S.
    Soldera, Sara V.
    Streutker, Catherine J.
    CURRENT ONCOLOGY, 2024, 31 (12) : 7770 - 7786
  • [6] Oxaliplatin in perioperative chemotherapy for gastric and gastroesophageal junction (GEJ) adenocarcinoma
    Fritsch, Ralph
    Hoeppner, Jens
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (04) : 285 - 291
  • [7] Neoadjuvant chemoimmunotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma
    Liu, Xiao
    Ma, Baozhen
    Zhao, Lingdi
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [8] HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment
    Kunz, Pamela L.
    Mojtahed, Amirkaveh
    Fisher, George A.
    Ford, James M.
    Chang, Daniel T.
    Balise, Raymond R.
    Bangs, Charles D.
    Cherry, Athena M.
    Pai, Reetesh K.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2012, 20 (01) : 13 - 24
  • [9] Phase II study of perioperative camrelizumab and XELOX for locally advanced gastric or gastroesophageal junction adenocarcinoma
    He, Jiaxing
    Zhang, Bo
    Zhou, Shuai
    Yang, Ying
    Han, Zhuo
    Wu, Tao
    Qiao, Qing
    Yang, Haicheng
    He, Xianli
    Wang, Nan
    CANCER SCIENCE, 2024, : 736 - 743
  • [10] Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population
    Martinez Lago, Nieves
    Vieito Villar, Maria
    Varela Ponte, Rafael
    Abdulkader Nallib, Ihab
    Carrera Alvarez, Juan Jose
    Antunez Lopez, Jose Ramon
    Lopez Lopez, Rafael
    Padin Iruegas, Maria Elena
    ECANCERMEDICALSCIENCE, 2020, 14
12345